Drugs / ABBV-722
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07599761 | May → Sep 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT07567781 | Apr → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07502417 | Mar → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07425899 | Feb → Aug 2026 overdue | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT07361367 | Jan → Mar 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06673238 | Oct 2024 → Jun 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-722 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07599761 ↗ |
| Route | Oral | “Oral Capsule” NCT06673238 ↗ |